Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
AFIB 
Acutus Medical Inc (AFIB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
01/28/2025: AFIB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 111.96% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 01/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.28M USD | Price to earnings Ratio - | 1Y Target Price 0.5 |
Price to earnings Ratio - | 1Y Target Price 0.5 | ||
Volume (30-day avg) 52389 | Beta -0.13 | 52 Weeks Range 0.03 - 0.22 | Updated Date 04/1/2025 |
52 Weeks Range 0.03 - 0.22 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-31 | When Before Market | Estimate - | Actual -0.047 |
Profitability
Profit Margin -47.36% | Operating Margin (TTM) -21.75% |
Management Effectiveness
Return on Assets (TTM) -14.26% | Return on Equity (TTM) -49.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 23022255 | Price to Sales(TTM) 0.06 |
Enterprise Value 23022255 | Price to Sales(TTM) 0.06 | ||
Enterprise Value to Revenue 1.14 | Enterprise Value to EBITDA 10.24 | Shares Outstanding 29912300 | Shares Floating 24308833 |
Shares Outstanding 29912300 | Shares Floating 24308833 | ||
Percent Insiders 8.28 | Percent Institutions 8.86 |
Analyst Ratings
Rating 3.67 | Target Price 1.5 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Acutus Medical Inc
Company Overview
History and Background
Acutus Medical, Inc. was founded in 2011, focused on developing, manufacturing, and commercializing innovative solutions for electrophysiology procedures. They aimed to improve the way cardiac arrhythmias are diagnosed and treated. In 2024, the company entered into a Restructuring Support Agreement with its secured lenders which will be subject to court approval in connection with the Company's commencement of voluntary Chapter 11 cases.
Core Business Areas
- Electrophysiology (EP) Mapping and Ablation: Develops and sells advanced cardiac mapping and ablation technologies used to treat heart rhythm disorders like atrial fibrillation and ventricular tachycardia.
Leadership and Structure
The leadership team includes individuals with experience in medical device technology and the electrophysiology field. The company is undergoing restructuring in 2024.
Top Products and Market Share
Key Offerings
- Acutus System: A diagnostic and therapeutic platform designed for high-definition cardiac mapping and ablation. Market share is difficult to determine due to limited data, but it competes with established players. Key competitors include Biosense Webster (JNJ), Abbott (ABT), and Medtronic (MDT). Revenue from this product is difficult to obtain publicly.
Market Dynamics
Industry Overview
The electrophysiology market is growing due to an aging population and increasing prevalence of cardiac arrhythmias. Advancements in technology, such as mapping and ablation systems, are driving market expansion.
Positioning
Acutus Medical seeks to establish a position as an innovator in cardiac arrhythmia management. Acutus Medical is a smaller competitor relative to Biosense Webster, Abbott, and Medtronic.
Total Addressable Market (TAM)
The global electrophysiology market is estimated to be multi-billion USD. Acutus Medical is positioned to capture a share of this TAM, particularly with its novel mapping and ablation technologies, but is limited by their current financial situation and chapter 11 status.
Upturn SWOT Analysis
Strengths
- Innovative Technology
- Novel Cardiac Mapping System
Weaknesses
- Limited Market Share
- Financial Instability
- Chapter 11 Status
- Heavy Reliance on Capital Markets
- Cash Burn
Opportunities
- Partnerships and Collaborations
- Expanding into Emerging Markets
- New product development (i.e. next generation cardiac mapping)
Threats
- Competition from Larger Players
- Technological Advancements by Competitors
- Regulatory Changes
- Reimbursement Pressures
- Continued financial losses
Competitors and Market Share
Key Competitors
- JNJ
- ABT
- MDT
Competitive Landscape
Acutus Medical faces intense competition from larger, well-established companies with greater financial resources and market reach. Acutus had novel technology but failed to capitalize on early leads.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been minimal, with revenue fluctuations and consistent net losses.
Future Projections: Future growth is uncertain, dependent on successful restructuring and potential acquisition.
Recent Initiatives: Recent strategic initiatives include restructuring efforts and potential sale of assets.
Summary
Acutus Medical is in a weak financial position, facing significant challenges due to its historical losses and negative cash flows. While it possesses innovative technology, it has struggled to compete with larger players. The recent chapter 11 filing highlights the company's struggles. Future success hinges on successful restructuring, a potential acquisition, or a significant turnaround in financial performance.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MDT
Medtronic PLC
MDT
Medtronic PLC
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Reports
- Company Website
Disclaimers:
This analysis is based on available public information and should not be considered financial advice. The information is subject to change and may not be entirely accurate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Acutus Medical Inc
Exchange NASDAQ | Headquaters Carlsbad, CA, United States | ||
IPO Launch date 2020-08-06 | CEO & CFO Mr. Takeo Mukai | ||
Sector Healthcare | Industry Medical Devices | Full time employees 85 | Website https://www.acutusmedical.com |
Full time employees 85 | Website https://www.acutusmedical.com | ||
Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.